Friday September 30, 2016 |
|||
09:00 – 12:45 |
Session 4: Inflammation and cell deathChairs: Gerry Melino (Rome/Leicester, UK) - Thomas Brunner (Konstanz, Germany)
|
||
|
|
09:30-10:00
|
John BERTIN (Pennsylvania, USA)
RIPK1 therapeutics—From concept to patients with immune-mediated inflammatory diseases
|
|
|
|
10:00-10:30
|
Domagoj VUCIC (San Francisco, USA)
Regulation of inflammation and cell death by RIP kinases
|
|
|
|
10:30-10:45
|
Ulrich Maurer (Freiburg, Germany)
SPATA2 promotes CYLD activity and regulates TNF-induced NF-kB signaling and cell death
|
|
10:45 - 11:15 |
Coffee break |
||
|
|
11:15-11:45
|
Henning WALCZAK (London, UK)
Cell death in cancer, inflammation and immunity
|
|
|
|
11:45-12:15
|
Seamus MARTIN (Dublin, Ireland)
TRAIL-induced Inflammatory signaling: a DISC with a Twist
|
|
|
|
12:15-12:30
|
Lynn Wong (Zurich, Switzerland)
RIPK3 promotes vascular permeability via VEGF/p38 axis to allow tumor cell extravasation independent of its kinase activity
|
|
12:30 – 14:00 |
Lunch on site |
||
14:00 – 15:30 |
Session 5: Death Receptors and caspase activating complexesChair : Núria Sánchez-Coll, Barcelona, Spain
|
||
|
|
14:00-14:30
|
Marion MACFARLANE (Leicester, UK)
A Unified Model for c-FLIP regulation of Caspase-8 and control of life/death decisions
|
|
|
|
14:30-15:00
|
Andreas VILLUNGER (Innsbruck, Austria)
Controlling cell death in and out of mitosis
|
|
|
|
15:00-15:15
|
Eli Arama (Rehovot, Israel)
Caretakers of tissue integrity: A non-apoptotic role of caspases in preventing unwanted cell migration and invasion
|
|
|
|
15:15-15:30
|
Dagmar Kulms (Dresden, Germany)
Caspase-8 promotes uncontrolled progression of cancer cells
|
|
15:30 - 16:00 |
Coffee break |
||
16:00 – 18:00 |
Session 6: Death modulators in the clinicChair: Joan Gil, Barcelona, Spain
|
||
|
|
16:00-16:15
|
Eric Eldering (Amsterdam, Netherlands)
BH3 mimetics as combination drugs and as profiling tools in CLL
|
|
|
|
16:15-16:30
|
Joan Montero (Boston, USA)
Using Dynamic BH3 Profiling to employ BH3 mimetics for improving cancer treatment
|
|
|
|
16:30-16:45
|
Markus Rehm (Stuttgart, Germany)
A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer building on tumor apoptosis competency
|
|
|
|
16:45-17:00
|
Ana Janic (Melbourne, Australia)
shRNA screens indicate that DNA repair is the process critical for p53-mediated tumour suppression
|
|
|
|
17:00-18:00
|
ECDO Honorary Lecture: Andreas STRASSER (Melbourne, Australia)
Which pro-survival BCL-2 family member should be targeted for the treatment of which cancer?
|
|
|
|
18:00-18:10
|
Poster and flash talk awards
|
|
|
|
18:10-18:20
|
Wrap-up
|
|
20:30 |
Conference dinner |
||
